Investigating the association between K198N coding polymorphism in EDN1 and hypertension, lipoprotein levels, the metabolic syndrome and cardiovascular disease

Simple item page
dc.contributor.authorWiltshire, S.
dc.contributor.authorPowell, B.
dc.contributor.authorJennens, M.
dc.contributor.authorMcCaskie, P.
dc.contributor.authorCarter, K.
dc.contributor.authorPalmer, L.
dc.contributor.authorThompson, P.
dc.contributor.authorMcQuillan, B.
dc.contributor.authorHung, J.
dc.contributor.authorBeilby, J.
dc.date.issued2008
dc.description.abstractEndothelin-1 is a potent vasoconstrictor in the body. Previous studies have identified associations between the coding polymorphism K198N and hypertension, systolic blood pressure and HDL levels. We sought to examine the evidence for these associations and, additionally, the association between K198N, insulin resistance, metabolic syndrome and coronary artery disease (CAD). We used generalised linear modelling to test K198N for association with hypertension and systolic blood pressure, lipid levels, insulin resistance scores and metabolic syndrome in a general cross-sectional community sample. Mean carotid intima media thickness and risk of carotid plaque were examined in the general population sample, and Gensini score was examined in a sample of patients with CAD. A case/control sample was used to examine the association of K198N with risk of CAD. There was no significant evidence for association between K198N and hypertension, systolic blood pressure, lipid levels, insulin resistance or metabolic syndrome in either population. The minor allele was marginally associated with increased mean IMT levels (P = 0.02) in the general population sample, although not with CAD in the case/control study or with the severity of disease in patients with CAD. In conclusion, we found no robust evidence for the associations between K198N and hypertension, systolic blood pressure or HDL levels seen in previous studies.
dc.description.statementofresponsibilitySteven Wiltshire, Brenda L. Powell, Michelle Jennens, Pamela A. McCaskie, Kim W. Carter, Lyle J. Palmer, Peter L. Thompson, Brendan M. McQuillan, Joseph Hung, John P. Beilby
dc.identifier.citationHuman Genetics, 2008; 123(3):307-313
dc.identifier.doi10.1007/s00439-008-0481-0
dc.identifier.issn0340-6717
dc.identifier.issn1432-1203
dc.identifier.orcidPalmer, L. [0000-0002-1628-3055]
dc.identifier.urihttp://hdl.handle.net/2440/86287
dc.language.isoen
dc.publisherSpringer-Verlag
dc.rights© Springer-Verlag 2008
dc.source.urihttps://doi.org/10.1007/s00439-008-0481-0
dc.subjectHumans
dc.subjectHypertension
dc.subjectInsulin Resistance
dc.subjectGlucose
dc.subjectLipoproteins
dc.subjectEndothelin-1
dc.subjectCase-Control Studies
dc.subjectCross-Sectional Studies
dc.subjectBlood Pressure
dc.subjectPolymorphism, Genetic
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectCholesterol, HDL
dc.subjectCoronary Artery Disease
dc.subjectSurveys and Questionnaires
dc.subjectMetabolic Syndrome
dc.titleInvestigating the association between K198N coding polymorphism in EDN1 and hypertension, lipoprotein levels, the metabolic syndrome and cardiovascular disease
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Translational Health Science publications